Peer-review publication, Clinical Infectious Diseases, has noted that Covaxin demonstrates protection against the new Covid-19 variants.
Bharat Biotech's Covaxin retained neutralising activity against emerging variants of coronavirus, as per a new study.
Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants.Yet another feather in its cap👍🏼@PMOIndia @nsitharaman @drharshvardhan @MoHFW_INDIA @ICMRDELHI @DBTIndia @doctorsoumya @BharatBiotech pic.twitter.com/AUhphvvivz
— suchitra ella (@SuchitraElla) May 15, 2021Advertisement
A study published by Clinical Infectious Diseases found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B1617 and B117, first identified in India and the UK, respectively.
ALSO READ: Cyclonic Tauktae very likely to intensify in next 24 hrs
A modest reduction in neutralisation by a factor of 1.95 was observed against B1617 variant compared to vaccine variant.
Despite this reduction, neutralising titre levels with B 1617 remain above levels expected to be protective.
No difference in neutralisation between B 117 first identified in the UK and vaccine strain was observed.
ALSO READ: India records 3.11 lakh new Covid cases, 4,077 deaths
The study was conducted in collaboration with National Institute of Virology and Indian Council of Medical Research.
